Vernon T. Bernardino

Shares of Prima BioMed Ltd (ADR) (NASDAQ: PNMD) are up 61 percent year-to-date, but still significantly below their 52-week high of $6.48. FBR’s Vernon T. Bernardino initiated coverage of the company with an Outperform rating and a price target of $6. The company has made...

In a report published Friday, MLV & Co analyst Vernon T. Bernardino initiated coverage on Rexahn Pharmaceuticals, Inc. (NYSE: RNN) with a Buy rating and $1.25 price target. In the report, MLV & Co noted, "We initiate coverage of Rexahn Pharmaceuticals Inc. (RNN) with a BUY rating and $1.25...

In a report published Thursday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating on Galena Biopharma (NASDAQ: GALE), and raised the price target from $3.00 to $5.00. In the report, MLV & Co noted, “We believe Galena Biopharma (GALE) has overcome the external challenges of 1H14...

In a report published Wednesday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating on Galmed Pharmaceuticals Ltd (NASDAQ: GLMD), and raised the price target from $19.00 to $24.00. In the report, MLV & Co noted, “Galmed Pharmaceuticals (GLMD) yesterday announced FDA approval for...

In a report published Tuesday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating and $16.00 price target on Galectin Therapeutics Inc (NASDAQ: GALT). In the report, MLV & Co noted, “Galectin Therapeutics (GALT) earlier today announced issuance of a US patent for composition and...

In a report published Wednesday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating on Galena Biopharma (NASDAQ: GALE), but lowered the price target from $5.00 to $3.00. In the report, MLV & Co noted, “We believe the negative reaction to Galena Biopharma's (GALE) disclosure of...

In a report published Thursday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating and $15.00 price target on BioCryst Pharmaceuticals (NASDAQ: BCRX). In the report, MLV & Co noted, “BioCryst Pharmaceuticals (BCRX) reported significant progress in 2Q14 highlighted by positive...

In a report published Wednesday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating on Galectin Therapeutics (NASDAQ: GALT), but lowered the price target from $16.00 to $27.00. In the report, MLV & Co noted, “Galectin Therapeutics (GALT) this morning announced results from the...

In a report published Tuesday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating and $20.00 price target on Galectin Therapeutics (NASDAQ: GALT). In the report, MLV & Co noted, “Albeit from 8 patients, an abundance of data support the safety and positive effects of GR-MD-02 on...

In a report published Thursday, MLV & Co. analyst Vernon T. Bernardino downgraded the rating on ImmunoCellular Therapeutics Ltd. (NYSE: IMUC) from Buy to Hold, and lowered the price target from $6.00 to $1.25. In the report, MLV & Co. noted, “We move from a BUY recommendation to HOLD and...